^
Association details:
| Biomarker: | EGFR mutation + BRCA1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
Published date:
10/23/2020
Excerpt:
...on the basis of the median mRNA expression of BRCA1 (BRCA1-high group [N = 46] and BRCA1-low group [N = 45]), in the BRCA1-high group, a statistically significant longer median PFS was found with gefitinib plus olaparib compared with gefitinib single agent...in the BRCA1-high group, median PFS was 12.9 months (95% CI: 8.6–20.3) in the gefitinib plus olaparib arm, compared with 9.2 months (95% CI: 5.7–12.7) in the gefitinib arm, p = 0.0449....Our data indicate that patients with EGFR-mutant NSCLC with high BRCA1 mRNA expression may derive a better outcome with gefitinib plus olaparib compared with gefitinib single agent.
DOI:
10.1016/j.jtocrr.2020.100113
Trial ID:
